Aurealis Therapeutics Announces Last Patient Last Treatment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, is pleased to announce that the last patient in its DIAMEND AUP-16 Phase 2 clinical trial on Diabetic Foot Ulcers (DFUs) has completed treatment. This important milestone marks the end of the treatment phase and initiates a 12-month […]
